Company News - VC and PE investment business - Medical and health professional investment - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2025 - 08 - 07

Aofumin® Selected into the Ministry of Industry and Information Technology's List of Biom Manufactur

Recently, China's Ministry of Industry and Information Technology (MIIT) announced the 2024 List of Biom Manufacturing Flagship Products (First Batch). A total of 36 flagship products were selected, covering multiple sub-sectors such as biomaterials, biochemicals, and biomedicine, fully demonstrating China's cutting-edge technological achievements in the field of biom manufacturing and setting benchmarks for future industrial development. Oryzogen's newly approved product, Aofumin®—Recombinant Human Albumin Injection (produced in rice)—was successfully selected, showcasing the...

浏览次数：0

查看详情>>

发布时间: 2025 - 08 - 04

Stepping Forward with Distinction! Efung Capital and Its Portfolio Companies Honored with Multiple I

Recently, Efung Capital and several of its invested biopharmaceutical companies have won multiple awards in various authoritative selections, thanks to their exceptional innovation capabilities and industry contributions. Notably, in the TMTPost 2025 H1 Pioneer List, Efung Capital was honored among the Top 20 in the Healthcare Sector. In the Hao Yue Capital Excellence Awards, Core Medical, Norling Bio, and Yingmingda were recognized as Best Innovative Medical Device Companies of the Year, while Coning Bio and Westlake Biosciences were honored as Best Innovative Pharmaceutical Co...

浏览次数：0

查看详情>>

发布时间: 2025 - 07 - 31

Monthly Health Review | July 2025

In July, Cloudbreak Therapeutics, a portfolio company of Efung Capital, successfully landed on the Hong Kong Stock Exchange. Oryzogen and Biotyx Medical became the first two companies to pass the IPO review under the Fifth Set of Standards on the STAR Market, while TnMab became the first company to have its IPO application accepted under the same standard since its restart.While continuing to gain momentum in the biopharmaceutical sector, other Efung Capital portfolio companies also delivered outstanding performance.01 Portfolio Company Listing and Financing ProgressCloudbreak TherapeuticsFirs...

浏览次数：1

查看详情>>

发布时间: 2025 - 07 - 30

Recognized and Included in National-Level Yearbook! Efung Capital Listed as an Outstanding Private E

The New Quality Productive Forces Seminar, co-hosted by the Macroeconomic Magazine of the National Development and Reform Commission and the Editorial Committee of the China Private Equity Fund Yearbook, was successfully held. During the seminar, the China Private Equity Fund Yearbook (2024) was officially released.To provide a more comprehensive overview of the industry's development, the Editorial Committee of the China Private Equity Fund Yearbook conducted a comprehensive evaluation of over 20,000 private equity fund managers in China across more than 20 dimensions, leveraging its data...

浏览次数：0

查看详情>>